**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 83915

**Manuscript Type:** CASE REPORT

***De novo* mutation of *NAXE* (*APOAIBP*)*-*relatedearly-onset progressive encephalopathy with brain edema and/or leukoencephalopathy-1: A case report**

Ding L *et al*. *De novo* mutation of PEBEL1

Le Ding, Ting-Ting Huang, Guo-Huan Ying, Shang-Yu Wang, Hai-Feng Xu, Hao Qian, Faiza Rahman, Xiao-Peng Lu, Hu Guo, Guo Zheng, Gang Zhang

**Le Ding,** Department of Neurology, Children’s Hospital of Nanjing Medical University, Nanjing 210008, Jiangsu Province, China

**Ting-Ting Huang, Guo-Huan Ying, Shang-Yu Wang, Hai-Feng Xu, Xiao-Peng Lu, Guo Zheng, Gang Zhang,** Department of Neurology, Children’s Hospital of Nanjing Medical University, Nanjing 210008, Jiangsu Province, China

**Hao Qian, Hu Guo,** Department of Neurology, Children’s Hospital of Nanjing Medical University, Nanjing 210008, Jiangsu Province, China

**Faiza Rahman,** Rehman Medical Institute Peshawar, Peshawar 39250, Pakistan

**Author contributions:** Zheng G and Ding L designed and performed the study; Huang TT, Ying GH, and Wang SY wrote the draft manuscript and were equal contributors to the study; Xu HF and Qian H collected the data; Rahman F, Lu XP, Guo H, and Zheng G carried out data analysis and language revising; All authors approved the final manuscript for submission.

**Supported by** the Epilepsy Research Fund of Chinese Anti-Epilepsy Association, No. CU-A-2021-17; Nanjing Municipal Health Bureau key project, No. ZKX21047; and the Postdoctoral Research Foundation of China, No. 2020M671550.

**Corresponding author: Gang Zhang, MD, PhD, Doctor,** Department of Neurology, Children’s Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing 210008, Jiangsu Province, China. zhanggangnjmu@126.com

**Received:** February 16, 2023

**Revised:** March 26, 2023

**Accepted:** April 12, 2023

**Published online:**

**Abstract**

BACKGROUND

Early-onset progressive encephalopathy with brain edema and/or leukoencephalopathy-1 (PEBEL1) is a rare autosomal recessive severe neurometabolic disease. The aim of this study was to investigate the clinical characteristics and genetic pathogenicity of PEBEL1 caused by rare *NAXE* (or *APOA1BP*)-related defects.

CASE SUMMARY

The patient was a girl aged 2 years and 10 mo. She was hospitalized due to walking disorder for > 40 d. The clinical manifestations were ataxia, motor function regression, hypotonia, and eyelid ptosis. Within 1 mo of hospitalization, she developed sigh breathing, respiratory failure, cerebellar edema and brain hernia, and finally she died. Changes were found in cranial imaging, including cerebellar edema accompanied by symmetrical myelopathy. Through whole exome sequencing, we detected *NAXE* compound heterozygous variation (NM 144772.3) c.733A>C (p. Lys245Gln, dbSNP: rs770023429) and novel variation c.370G>T (p.Gly124Cys) in the germline gene. The clinical features and core phenotypes of this case were consistent with 18 previously reported cases of PEBEL1.

CONCLUSION

This is the first case of NAXE-related PEBEL1 with severe clinical phenotype in Mainland China. The p.Gly124Cys mutation discovered in this case has enriched the pathogenic variation spectrum of *NAXE*.

**Key Words:** Encephalopathy; Respiratory insufficiency; Cerebral edema; *NAXE* gene; *APOAIBP* gene; Novel variation; Case report

Ding L, Huang TT, Ying GH, Wang SY, Xu HF, Qian H, Rahman F, Lu XP, Guo H, Zheng G, Zhang G. De novo mutation of *NAXE* (*APOAIBP*)-related early-onset progressive encephalopathy with brain edema and/or leukoencephalopathy-1: A case report. *World J Clin Cases* 2023; In press

**Core Tip:** We report a girl with early-onset progressive encephalopathy with brain edema and/or leukoencephalopathy-1 (PEBEL1), and review the reported cases in the literature. The disease has rapid progression with an unfavorable prognosis. Gene detection is the only diagnostic method. We report the first case of PEBEL1 with severe clinical phenotype in Mainland China.

**INTRODUCTION**

Early-onset progressive encephalopathy with brain edema and/or leukoencephalopathy 1 (PEBEL1, OMIM: #617186) is a rare autosomal recessive severe neurometabolic disease[[1](#_ENREF_1" \o "Kremer, 2016 #430)]. At present, more than 10 cases have been reported worldwide since 2016[[1-3](#_ENREF_1)], but only one case has been reported in China. In this study, the clinical data of a child with PEBEL1 treated in the Department of Neurology, Children’s Hospital Affiliated to Nanjing Medical University in July 2021 were retrospectively analyzed, and the related literature was reviewed to improve the understanding, diagnosis, and treatment of the disease.

**CASE PRESENTATION**

***Chief complaints***

The patient was a girl aged 2 years and 10 mo. She was hospitalized because of walking disorder for > 40 d.

***History of present illness***

Forty days ago, she presented with unstable walking and was suspected of having synovitis and stayed in bed at home. She had an episode of fever 30 d prior to that, and the fever spike was 38°C. Blood examination in the outpatient clinic showed leukocytosis, and the fever subsided after oral administration of cephalosporin for 1 wk. During this period, the patient did not leave bed or walk again. Two weeks ago, she developed binocular movement disorder, slow eyeball pursuit, and slight drooping eyelids. Gradually, the patient had wobbling in sitting, and resisted sitting, and cried when urinating, so she was admitted to hospital.

***History of past illness***

There was a sudden suspicious episode of choking during a meal 3 mo ago, with gaze, unconsciousness, and clenched teeth for 6-7 min, which was relieved after patting on the back and vomiting. There was no abnormality in computed tomography (CT) examination of the head and chest in the local hospital. She was scratched by a cat 2 mo ago and was injected with rabies vaccine three times in 2 wk. Fifty days ago, she suddenly developed generalized weakness and bowed her head during playing, and then her limbs became stiffer, which lasted for about 1 min, followed by vomiting and incontinence. The follow-up was as usual, and the parents made an appointment for a video electroencephalogram examination, which was not done because the patient was immobilized at home.

***Personal and family history***

There was no special personal history, and the milestone of intellectual and motor development was normal since childhood. Her parents were in good health and denied any consanguinity. The 11-year-old brother also was in good health.

***Physical examination***

There was no special personal history, and the milestone of intellectual and motor development was normal since childhood. Her parents were in good health and denied any consanguinity. The 11-year-old brother also was in good health.

***Laboratory examinations***

After admission, blood routine tests were done. Biochemical studies, blood ammonia, blood lactic acid, erythrocyte sedimentation rate, procalcitonin, six items of coagulation, complete set of autoantibodies, cellular immunity, humoral immunity, four items of infectious diseases, and seven items of thyroid function tests were normal. Screening of hereditary metabolic diseases in hematuria was not abnormal. Four items of tumor: nonspecific enolase was 40.33 ng/mL (0–16.3 ng/mL), a-fetoprotein, carcinoembryonic antigen and carbohydrate antigen 19-9 were normal. Cerebrospinal fluid biochemistry showed: protein 0.27 g/L and glucose 4.82 mmol/L. Routine cerebrospinal fluid analysis showed: nucleated cell count 3 × 106/L; cerebrospinal fluid-MP, epidermolysis bullosa, cytomegalovirus and herpes simplex virus deoxyribonucleic acid was negative; cerebrospinal fluid and blood autoimmune encephalitis antibody, central demyelination antibody, and peripheral nerve disease spectrum antibody were negative; and cerebrospinal fluid pathogen macro gene was negative.

***Imaging examinations***

Plain CT of the chest and abdomen showed no abnormalities, with normal abdominal contents and obvious bladder filling. No abnormality was found in skull magnetic resonance imaging (MRI), magnetic resonance (MR) angiography and MR venography on day 2 after admission, and spinal MRI showed T2 high signal in the spinal cord at the T7–10 level (poor coordination, heavy artifact) (Figure 1). Electroencepholography showed background moderation, poor rhythmicity and responsiveness, with spike waves and spike slow waves in bilateral anterior and middle temporal regions during sleep, which were not synchronized between left and right.

***Further diagnostic work-up***

With the approval of the Medical Ethics Committee of the hospital (approval number: 202111116-1) and the informed consent of the guardians of the child, 2 mL peripheral blood from the patient and her parents were taken for whole exome sequencing (Beijing Zhiyin Dongfang). The whole-exome library was constructed using xGen ®Exome Research Panel v1.0 (IDT, United States) capture probe, and the NovaSeq 6000 (Illumina, United States) series sequencer was used for high-throughput sequencing. The compound heterozygous mutations c.733A>C (p.Lys245Gln, dbSNP: rs770023429) and c.370G>T (p.Gly124Cys) in *NAXE* (*APOA1BP*) inherited from her parents were identified and verified by Sanger sequencing (Figure 2). According to the American Society of Medical Genetics 2015[[3](#_ENREF_3)], Lys245Gln (reported in the PS1+PM1, gnomAD East Asia MAF: 0.0019, PEBEL1 case[[4](#_ENREF_4)]) was likely pathogenic and Gly124Cys (PM1+PM2+PP3, no MAF record) was annotated as unknown pathogenicity variation. The variant amino acid residues were analyzed using VarSite (https://www.ebi.ac.uk/thornton-srv/databases/VarSite); a variant analysis tool provided by European Institute of Bioinformatics, and the two variants were both highly evolutionarily conservative (Figure 3). The conservatism of Lys245Gln in 174 homologous sequences was 0.5, which was lower than that of Gly124Cys in 190 homologous sequences (0.1). Using SWISS-MODEL and Swiss-pdb Viewer software to predict the pathogenicity of the mutation sites, the protein structure, the residues of the mutation site, and the functional sites nearby, it is suggested that the possible pathogenicity, c.733A>C site is shown in Figure 4, c.370G>T mutation site is shown in Figure 5.

**FINAL DIAGNOSIS**

The patient was diagnosed with PEBEL1.

**TREATMENT**

After admission, a detailed examination was done and the patient was treated with acyclovir, dexamethasone (0.5 mg/kg), gammaglobulin (2 g/kg), and other anti-inflammatory drugs. Urinary retention occurred on the day 3 and indwelling catheterization was performed. On day 5, the patient developed confusion, irregular respiratory rhythm, and poor response, and was transferred to the pediatric intensive care unit. This was followed by a decrease in heart rate and blood oxygen saturation, and she received cardiopulmonary resuscitation and mechanical ventilation. Nutritional support with levocarnitine and coenzyme Q10 was given, and simultaneous high-dose methylprednisolone (20 mg/kg) was given for 3 d, and plasma exchange was performed for 2.5 h on day 10. Bilateral pupil dilation, the disappearance of light reflex and deep coma appeared on day 12. Cranial CT suggested diffuse cerebellar swelling with hydrocephalus and ventricular dilatation, and further improvement of cranial CT angiography enhancement suggested an unclear display of straight sinus and no significant parenchymal enhancing mass shadow was seen (Figure 6). On day 14, after multidisciplinary team discussion, intraventricular drilling and drainage, and intracranial pressure probe implantation were performed. About 100 mL cerebrospinal fluid was drained after surgery, and the intracranial pressure was maintained at 20–74 mmHg. On day 17, whole exosome sequencing detected *NAXE* compound heterozygous mutation, and we added 100 mg nicotinamide intravenous drip. The patient gradually deteriorated and developed a slow heart rate, hypotension, central diabetes insipidus and electrolyte disturbance, and was treated with symptomatic support such as volume expansion, plasma, albumin, electrolyte supplement, blood transfusion, and maintenance of blood pressure using dopamine, norepinephrine, epinephrine, and posterior pituitary hormone. On day 26, cerebral MRI showed cerebellar swelling, possible herniation of the cerebellar curtain notch, and multiple abnormal signals in the brain parenchyma and cervical spinal cord (Figure 7).

**OUTCOME AND FOLLOW-UP**

After 30 d, the child became brain dead and her parents abandoned treatment.

**DISCUSSION**

PEBEL1 is a rare fatal encephalopathy caused by a double allele mutation of *NAXE* (*APOA1BP*) on chromosome 1q22. In 2016, Spiegel[[2](#_ENREF_2" \o "Spiegel, 2016 #422)] reported for the first time that five children from Israel, who were near relatives were affected. The age at onset was 6-12 mo, with loss of motor function after infection, bedridden at the age of 2 years, mechanically ventilated, and finally in a vegetative state. Four patients died between 1 and 3 years of age, and one child was supported by a ventilator until 5.5 years of age, and MRI revealed deep white matter lesions. Kremer *et al*[[1](#_ENREF_1" \o "Kremer, 2016 #430)] summarized the clinical features of five patients who presented with infantile/early childhood onset, usually caused by fever with rapidly progressive deterioration of neurological function. The patients showed muscular hypotonia, motor development regression, cognitive loss, ataxia, nystagmus, seizures, quadriplegia, and respiratory failure, which eventually led to a vegetative state and brain death. Brain and spinal cord imaging may show white matter abnormalities, cerebral atrophy, cerebellar edema, and myelopathy. It has also been reported[[1](#_ENREF_1" \o "Kremer, 2016 #430)] that a large area of subacute bullous dermatosis occurred within a few weeks after the onset of neurological symptoms.

The keywords NAXE, APOAIBP, NAD(P)HX epimerase and AIBP were searched in PubMed, ClinVar, Wanfang, and CNKI, and papers with clear clinical data were selected. As of October 2021, 17 reported pathogenic *NAXE* variants in 12 cases had been collected (Table 1). These included 11 missense mutations (Glu85Asp, Ala94Asp, Gly121Arg, Arg129Pro, Gly189Ser, Ile214Val, Ile214Ser, Asp218Asn, Asp218Val, Lys245Gln and Gly253Ser, 64.7%, 11/17), two splice site mutations (c. 516+1G>A and c. 665-1G>A, 11.8%, 2/17), two nonsense mutations (Tyr59Ter and Gln66Ter,11.8%,2/17), one frameshift mutation (Ala248fs, 5.9%, 1/17), and one deletion/insertion mutation (c.804\_807delinsA/Lys270del, 5.9%, 1/17)[[1](#_ENREF_1),[2](#_ENREF_2),[4-7](#_ENREF_4)]. The Lys245Gln detected in the present case was the reported homozygous pathogenic variant[[4](#_ENREF_4" \o "Trinh, 2020 #428)]. The clinical characteristics of the present case and 18 previous cases from 12 families are summarized as follows[[1-8](#_ENREF_1" \o "Kremer, 2016 #430)]. The age of onset of PEBEL1, except for a German family with two girls who developed the disease at the age of 20 and 22 years, respectively[[4](#_ENREF_4" \o "Trinh, 2020 #428)], was < 3 years in 89% of the patients (17/19). Most cases were induced by febrile infection (58%, 11/19). The main manifestations were rapidly progressive or recurrent respiratory insufficiency (79%, 15/19), motor cognitive regression (79%, 15/19), decreased muscle strength and muscle tone (79%, 15/19), ataxia (42%, 8/19), nystagmus (32%, 6/19), strabismus (21%, 4/19), seizures (21%,4/19), bilateral blepharoptosis (11%, 2/19), dysarthria and dysphagia (21%, 4/19), and skin erythema rash (11%, 2/19). Eleven of the 19 patients had brain MRI changes, including brain edema (55%, 6/11), brain white matter abnormalities (27%, 3/11), brain atrophy (27%, 3/11), myelopathy (27%, 3/11), cortical and basal ganglia lesions (10%, 1/11), and brain stem and intracranial hemorrhage (10%, 1/11). The cerebrospinal fluid lactic acid test was elevated in seven of the 19 cases, (71%, 5/7), and 12 of 19 cases died of end-stage coma within 3 years of age (63%, 12/19).

In the present case, the patient had normal development since childhood and had a history of rabies vaccination in the early stage of onset, and the nervous system symptoms were gradually aggravated after fever. It was possible to be misdiagnosed as an immune inflammatory disease; however, the condition still deteriorated rapidly after active immunotherapy, with respiratory failure, cerebellar edema, and cerebral herniation, which posed major challenges to clinicians. Carefully combing the medical history, we found that the patient had two paroxysmal events within 3 mo of PREBLE1 onset, which were suspected to be epileptic seizures. Physical examination on admission showed that the patient had droopy eyelids, eye movement disorder, and hypotonia of the extremities, and the pathological reflex was positive and the spinal cord lesions were symmetrical. Due to the rapid change of the disease, electromyographic examination was not conducted, and it was necessary to be alert to the possibility of hereditary metabolic diseases (mitochondria), so gene detection was performed as soon as possible. The clinical features, imaging findings, and disease progression of the child were consistent with the characteristics of PEBEL1.

The human nicotinamide nucleotide repair system consists of two chaperone enzymes: NAD(P)HX differential isomerase (NAXE, formerly known as APOA1BP, OMIM:608862), which converts R-NAD(P)HX to S-NAD(P)HX, and the NAD(P)HX dehydratase (NAXD, formerly CARKD, OMIM:615910), which converts SNAD(P)HX back to NAD(P)H[[9](#_ENREF_9)] in an ATP-dependent manner. The presence of NAD(P)HX repair enzymes in all tissues and species, coupled with the core metabolism of their cofactors which play a protective role, suggests that the repair system is essential for life maintenance[[10](#_ENREF_10" \o "Marbaix, 2014 #433)].

The *NAXE* (*APOAIBP*) gene encodes NAD(P)HX differential isomerase or apolipoprotein AI binding protein (AIBP), located on the 1q22 chromosome. There are five transcripts, including six exons (https://www.uniprot.org/uniprot/Q8NCW5), spanning 2.5 kb and composed of 288 amino acids. It contains mitochondrial transport peptide (residues 1–47), NAD(P)H hydrate isomerase (residues 48–288), yjefn terminal domain (residues 65–275), two NAD(P)HX region (residues 119–223, residues 189–195). NAXE protein exists in cerebrospinal fluid and urine, and is widely expressed in the kidneys, heart and liver[[11](#_ENREF_11" \o "Ritter, 2002 #435)]. In *in vitro* experiments in fibroblasts from PEBEL1 patients, NAXE deficiency caused a significant increase in circulating NADHX and two NADHX isoforms (S and R isoforms) under normal body temperature (37°C). The elevated levels of circulating NADHX were greater in NAXE-deficient cells after treatment with heat stress (40°C), and the elevation of S- and R-type NADHX isoforms was attenuated. In addition, the activity of intact mitochondria in the muscle tissue of two patients also decreased significantly[[1](#_ENREF_1" \o "Kremer, 2016 #430)]. These prove that NAXE deficiency leads to the accumulation of the toxic metabolites of the biochemical reaction cofactors NADH and NADPH, circulating NADHX, then affects the oxidative phosphorylation of mitochondria and leads to the deficiency/disorder of mitochondrial energy metabolism. Therefore, it can be predicted that the brain with high demand for energy supply produced by mitochondria is particularly vulnerable to the damage of NAD(P)HX repair, which can also explain the deterioration of neurological symptoms clinically in children after fever. Although *NAXE* is highly expressed in the human brain (https://gtexportal.org/home/gene/NAXE), the mechanism of its defect in the central nervous system is still unclear.

Vitamin B3 and coenzyme Q are specific treatments for elevated NAD+ levels, so they are also expected to benefit PEBEL1 patients. A 22-year-old female patient reported by TRINH[[4](#_ENREF_4)] in Germany, in addition to receiving vitaminB3 treatment (niacin 40 mg bid to 2 × 40 mg bid), received anticonvulsant therapy (topiramate 50 mg bid, clomazone 20 mg/d, lamotrigine 300 mg/d, levetiracetam 1000 mg/d, piracetam 2400 mg/d, vitamin D3, esomeprazole, and laxative). The patient survived up to 29 years of age and had significant improvement in spasticity with some recovery in motor abilities. In our case, the patient had acute onset and progressed rapidly. Although nicotinamide (vitamin B3) and coenzyme Q were used on day 17 of onset, they still could not reverse/delay brain edema, and the fatal pathological changes need to be proved by practice.

**CONCLUSION**

This is the first case of severe clinical phenotypic PEBEL1 reported in Mainland China, and a compound heterozygous variation of the *NAXE* gene was detected and a new variant Gly124Cys was identified, which expanded the pathogenicity variation spectrum of PEBEL1. Due to the rapid progress of PEBEL1 and mostly sporadic cases, its early presentation, often characterized by acute onset of fever-induced deterioration of central nervous function or even cerebral edema, is not easy to indicate hereditary diseases, which may be an important reason for the lack of awareness of the disease among clinicians. For patients suspected of PEBEL1, vitamin B3 and coenzyme Q therapy should be tried first, and gene detection should be carried out as soon as possible to make a definite diagnosis. For the family of this case, we suggest that the *NAXE* mutation test should be used as a necessary part of prenatal genetic screening.

**REFERENCES**

1 **Kremer LS**, Danhauser K, Herebian D, Petkovic Ramadža D, Piekutowska-Abramczuk D, Seibt A, Müller-Felber W, Haack TB, Płoski R, Lohmeier K, Schneider D, Klee D, Rokicki D, Mayatepek E, Strom TM, Meitinger T, Klopstock T, Pronicka E, Mayr JA, Baric I, Distelmaier F, Prokisch H. NAXE Mutations Disrupt the Cellular NAD(P)HX Repair System and Cause a Lethal Neurometabolic Disorder of Early Childhood. *Am J Hum Genet* 2016; **99**: 894-902 [PMID: 27616477 DOI: 10.1016/j.ajhg.2016.07.018]

2 **Spiegel R**, Shaag A, Shalev S, Elpeleg O. Homozygous mutation in the APOA1BP is associated with a lethal infantile leukoencephalopathy. *Neurogenetics* 2016; **17**: 187-190 [PMID: 27122014 DOI: 10.1007/s10048-016-0483-3]

3 **Richards S**, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015; **17**: 405-424 [PMID: 25741868 DOI: 10.1038/gim.2015.30]

4 **Trinh J**, Imhoff S, Dulovic-Mahlow M, Kandaswamy KK, Tadic V, Schäfer J, Dobricic V, Nolte A, Werber M, Rolfs A, Münchau A, Klein C, Lohmann K, Brüggemann N. Novel NAXE variants as a cause for neurometabolic disorder: implications for treatment. *J Neurol* 2020; **267**: 770-782 [PMID: 31745726 DOI: 10.1007/s00415-019-09640-2]

5 **Yu D**, Zhao FM, Cai XT, Zhou H, Cheng Y. [Clinical and genetic features of early-onset progressive encephalopathy associated with NAXE gene mutations]. *Zhongguo Dang Dai Er Ke Za Zhi* 2018; **20**: 524-258 [PMID: 30022751 DOI: 10.7499/j.issn.1008-8830.2018.07.002]

6 **Incecık F**, Ceylaner S. Early-onset progressive encephalopathy associated with NAXE gene variants: a case report of a Turkish child. *Acta Neurol Belg* 2020; **120**: 733-735 [PMID: 31758406 DOI: 10.1007/s13760-019-01242-z]

7 **Mohammadi P**, Heidari M, Ashrafi MR, Mahdieh N, Garshasbi M. A novel homozygous missense variant in the NAXE gene in an Iranian family with progressive encephalopathy with brain edema and leukoencephalopathy. *Acta Neurol Belg* 2022; **122**: 1201-1210 [PMID: 34120322 DOI: 10.1007/s13760-021-01717-y]

8 **Choi SH**, Agatisa-Boyle C, Gonen A, Kim A, Kim J, Alekseeva E, Tsimikas S, Miller YI. Intracellular AIBP (Apolipoprotein A-I Binding Protein) Regulates Oxidized LDL (Low-Density Lipoprotein)-Induced Mitophagy in Macrophages. *Arterioscler Thromb Vasc Biol* 2021; **41**: e82-e96 [PMID: 33356389 DOI: 10.1161/ATVBAHA.120.315485]

9 **Marbaix AY**, Noël G, Detroux AM, Vertommen D, Van Schaftingen E, Linster CL. Extremely conserved ATP- or ADP-dependent enzymatic system for nicotinamide nucleotide repair. *J Biol Chem* 2011; **286**: 41246-41252 [PMID: 21994945 DOI: 10.1074/jbc.C111.310847]

10 **Marbaix AY**, Tyteca D, Niehaus TD, Hanson AD, Linster CL, Van Schaftingen E. Occurrence and subcellular distribution of the NADPHX repair system in mammals. *Biochem J* 2014; **460**: 49-58 [PMID: 24611804 DOI: 10.1042/BJ20131482]

11 **Ritter M**, Buechler C, Boettcher A, Barlage S, Schmitz-Madry A, Orsó E, Bared SM, Schmiedeknecht G, Baehr CH, Fricker G, Schmitz G. Cloning and characterization of a novel apolipoprotein A-I binding protein, AI-BP, secreted by cells of the kidney proximal tubules in response to HDL or ApoA-I. *Genomics* 2002; **79**: 693-702 [PMID: 11991719 DOI: 10.1006/geno.2002.6761]

**Footnotes**

**Informed consent statement:** Written informed consent for publication was obtained from the parents.

**Conflict-of-interest statement:** All the authors have no financial relationship with any commercial entity with a potential interest in the subject of this manuscript.

**CARE Checklist (2016) statement:** All the authors have no financial relationship with any commercial entity with a potential interest in the subject of this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 16, 2023

**First decision:** March 14, 2023

**Article in press:**

**Specialty type:** Clinical Neurology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Lucke-Wold B, United States; Reis F, Brazil **S-Editor:** Liu JH **L-Editor:** A **P-Editor:**


**Figure Legends**




**Figure 1 The imaging findings of brain and spinal cord magnetic resonance on day 2 after admission.** A and B: T2-weighted magnetic resonance imaging and fluid-attenuated inversion-recovery imaging of the head, respectively, showed no abnormal signals in the brainstem, cerebellum, and cerebral cortex; C: Magnetic resonance arterial angiography of the head was normal; D: Brain magnetic resonance venography was normal; E and F: T2 hyperintensity in T7-10 horizontal transverse section of thoracic spinal cord (indicated by red arrow).




**Figure 2 Verification of *NAXE* (NM\_144772.3) complex heterozygous variation in the patient by Sanger sequencing.**




**Figure 3 Conservative analysis of *NAXE* variation sites.** The variants are indicated in red, and the new variants are expressed in italics. The analysis tool used EMBL-EBI VarSite (https://www.ebi.ac.uk/thornton-srv/databases/VarSite) and compared > 100 homologous sequences in different species.




**Figure 4 Structural analysis of wild-type and the variant *APOA1BP* with c.733A>C mutation.** A: the three-dimensional structure of wild-type (WT); B: the three-dimensional structure of the mutant; C: the residue of missense mutant site together with the nearby functional site of WT; D: the residue of missense mutant site together with the nearby functional site of the mutant. Residues of the mutant sites are highlighted in green.



**Figure 5 Structural analysis of wild-type and variant *APOA1BP* with c.370G>T mutation.** A: the three-dimensional structure of wild-type (WT); B: the three-dimensional structure of the mutant; C: the residue of missense mutant site together with the nearby functional site of WT; D: the residue of missense mutant site together with the nearby functional site of the mutant. Residues of the mutant sites are highlighted in green solid line. The computed hydrogen bonds are shown as green dashed lines and red arrow.



**Figure 6 The imaging findings of head computed tomography on day 12 after admission.** A: There was a large area of diffuse hypointense signal in the posterior fossa, and the cerebellar parenchymal structure was unclear; B: There was marked dilatation of the supratentorial ventricles and obstructive hydrocephalus with paraventricular edema; C: No parenchymal enhancement mass was found on contrast-enhanced scan; D: The sagittal view showed supratentorial elevation with diffuse brain swelling on contrast-enhanced scan.



**Figure 7 The imaging findings of head magnetic resonance on day 26 after admission.** A-C: T2-weighted imaging showed blurred boundary between gray matter and white matter, structural disorder of brain stem and cerebellar hemisphere, and multiple long T2 signal shadows; D-F: Fluid-attenuated inversion-recovery (FLAIR) images showed blurred gray and white matter, disordered structure, high FLAIR signal around the cerebellum and lateral ventricle, and significant narrowing of the lateral ventricle.

**Table 1 General situation and clinical features of our case and 12 previously reported cases**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Gender** | **Nationality** | ***NAXE* variation** | **Age at onset** | **Age at death** | **Inducement** | **Clinical characteristics** | **MRI features** |
| 1[this study] | F | China | p.Lys245Gln; p.Gly124Cys | 2 yr 10 mo | 3 yr | Fever | Respiratory insufficiency, motor regression, poor eye contact, hypotonia, dysphagia, nystagmus, drowsiness, bilateral ptosis | Cerebellar edema, myelopathy |
| 2[[1](#_ENREF_1)] | M | China | p.Glu85Asp; p.Gly121Arg | 2 yr | Unknown | Fever/infection | Decreased muscle tone of the extremities, weakening abdominal wall reflex and cremaster reflex, unsteady walking, finger-nose test and Romberg sign positive | Brain atrophy |
| 3[[6](#_ENREF_6)] | M | Iran | p.Gly189Ser | 2 yr | 3 yr | Unknown | Neuromotor development and cognitive regression, unclear speech, uncoordinated hand movement, nystagmus, poor coordination, impaired finger–nose test, increased lactic acid in cerebrospinal fluid | Bilateral temporal cortex, basal ganglia lesions |
| 4[[2](#_ENREF_2)] | M | Turkey | p.Arg129Pro; p.Ile214Ser | 1.5 yr | 3 yr | Unknown | Cognitive impairment, axial dystonia, quadriplegia, strabismus, increased deep tendon reflex of lower extremities, ankle clonus, bilateral Babinski sign positive | Not significant |
| 5-1[[5](#_ENREF_5)] | F | Germany | c.665-1G>A; p.Gly253Ser | 22 yr | > 29 yr | Unknown | Recurrent illness, initial headache, respiratory insufficiency, developmental disabilities, seizures, myoclonus, comatose state, cerebellar ataxia, spastic quadriplegia, dysarthria, dysphagia, cervical dystonia, non-infectious fever, psychiatric symptoms | Not significant |
| 5-2[[5](#_ENREF_5)] | F | Germany | c.665-1 G>A; p.Gly254Ser | 20 yr | 22 yr | Alcohol, cannabis | Recurrent illness, initial headache, respiratory insufficiency, comatose state, cerebellar ataxia, cognitive impairment, myoclonus, nystagmus, diplopia, neuropsychiatric symptoms, hypokinesia | Not significant |
| 6[[5](#_ENREF_5)] | M | Saudi Arabia | p.Lys245Gln | Unknown | Unknown | Unknown | Respiratory insufficiency, progressive motor development delay, dystonia, septicemia | Unknown |
| 7[[5](#_ENREF_5)] | M | Jordan | p.Asp218Asn | 1 d | Unknown | Unknown | Respiratory insufficiency, coma, developmental disabilities, hypodystonia, strabismus, bradycardia, decreased serum creatinine , hypoventilation, thrombocytosis, mitral regurgitation | White matter abnormalities, brainstem MRI signal intensity abnormalities, intracranial hemorrhage, brain atrophy |
| 8[[5](#_ENREF_5)] | M | India | p.Ile214Val | Unknown | Unknown | Unknown | Developmental disabilities, elevated lactic acid in cerebrospinal fluid, pigmented retinopathy, elevated serum creatine phosphokinase |  |
| 9[[3](#_ENREF_3)] | M | Gambia | p.Tyr59Ter | 20 mo | 21 mo | Fever/infection | Recurrent illness, respiratory insufficiency, coma, ataxia, seizures, bullous dermatosis, elevated lactic acid in cerebrospinal fluid and blood, quadriplegia, nystagmus, torticollis | Cerebral edema, myelopathy |
| 10[[3](#_ENREF_3)] | F | Croatia | p.Gln66\*, c.516+1G>A | 15 mo | 2 yr | Fever/infection | Recurrent illness, respiratory insufficiency, coma, delayed psychomotor development, tremor, ataxia, dystonia, edema and erythema rash, elevated lactic acid in cerebrospinal fluid | Cerebral edema, brain atrophy, myelopathy |
| 11[[3](#_ENREF_3)] | M | Germany | p.Lys270del | 16 mo | 18 mo | Fever/infection | Rapid progression, respiratory insufficiency, progressive ataxia, developmental disabilities, coma, elevated cerebrospinal fluid lactic acid, nystagmus, bilateral ptosis | Cerebral edema |
| 12-1[[3](#_ENREF_3)] | M | Poland | p.Asp218Val; p.Ala248fs | 16 mo | 29 mo | Unknown | Recurrent illness, respiratory insufficiency, coma, ataxia, dystonia, focal redness, skin changes in psoriasis of the neck, increased lactic acid in cerebrospinal fluid, dysarthria, nystagmus | Cerebral edema |
| 12-2[[3](#_ENREF_3)] | M | Poland | p.Asp218Val; p.Ala248fs | 8 mo | 2 yr | Unknown | Recurrent illness, respiratory insufficiency, coma, seizures, dystonia, elevated lactic acid in cerebrospinal fluid | Brain dysplasia, acute hydrocephalus |

F, female; M, male; MRI: Magnetic resonance imaging.